1st Edition

The Pharmaceutical Index 2013 Worldwide NCEs

Edited By Pharmacodia (Beijing) Co.,Ltd. Copyright 2016
    546 Pages
    by CRC Press

    An ideal drug candidate should possess good pharmacological activity, absorption, distribution, metabolism, excretion and toxicity properties. Historically, there are around 6,000 drugs being used in humans and approximately 3,000 still in clinical use, not including herbal medicines. This Pharmaceutical Index series focuses on the profiles of 500 pharmaceutically marketed products from the past two decades. Professor Dr. K. Barry Sharpless is Honorary Editor-in-Chief of this first Index by Pharmacodia. The volume includes 24 NCEs worldwide approved drugs in 2013. Pharmacodia plan to publish two further volumes which will feature 2014 NCEs (32 drugs) and 2015 NCEs (25 drugs).

    Executive Summary

    Chapter 1: Acotiamide Hydrochloride Hydrate

    Chapter 2: Afatinib Dimaleate

    Chapter 3: Canagliflozin Hemihydrate

    Chapter 4: Cetilistat

    Chapter 5: Cobicistat

    Chapter 6: Dabrafenib Mesylate.

    Chapter 7: Dimethyl Fumarate

    Chapter 8: Dolutegravir Sodium

    Chapter 9: Efinaconazole

    Chapter 10: Elvitegravir

    Chapter 11: Glycerol Phenylbutyrate

    Chapter 12: Ibrutinib

    Chapter 13: Istradefylline

    Chapter 14: Levomilnacipran Hydrochloride

    Chapter 15: Macitentan

    Chapter 16: Olodaterol Hydrochloride

    Chapter 17: Ospemifene

    Chapter 18: Pomalidomide

    Chapter 19: Riociguat

    Chapter 20: Simeprevir Sodium

    Chapter 21: Sofosbuvir

    Chapter 22: Topiroxostat

    Chapter 23: Trametinib Dimethyl Sulfoxide

    Chapter 24: Vortioxetine Hydrobromide

    Appendix I. Abbreviation

    Appendix II. Worldwide Approved NCEs (2001-2014)

    Biography

    Pharmacodia (Beijing) Co. Ltd

    ‘This new series of Pharmaceutical Indexes will be a boon in academia and the pharmaceutical industry, and provide, as well, a significant addition to the therapeutics discovery arsenal. It should also find a wide audience in government, and the business community.’
    – K. Barry Sharpless, Nobel Prize Winner in Chemistry, 2001.

    ‘The most fruitful basis for the discovery of a new drug is to start with an old drug.’
    – James W. Black, Nobel Prize Winner in Physiology or Medicine, 1998.